Pyelonephritis Clinical Trial
— PROPAOfficial title:
New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency
Verified date | June 2011 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
The prevalence of acute pyelonephritis (PNA) is 60-75 000/year. They are traditionally classified as uncomplicated (60-65%) and complicated. If it is assumed that the uncomplicated PNA can be treated as outpatients with a cure rate of over 80%, the second group is very heterogeneous. Some patients are severely infected. But others, despite an older age, structural urologic abnormalities or a controlled history, have no risk factors and can be simply managed. The investigators propose to reclassify the PNA into 3 categories: uncomplicated PNA (PNA-1), the PNA of moderate severity (PNA-2), the major PNA (PNA-3) to test whether the PNA-2 can benefit from the same outpatient care that the PNA-1. The existence of biological markers of the severity of bacterial infections would further support a tailored approach. The pro-adrenomedullin (pro-ADM), successfully tested to identify severe community acquired pneumonia, is a an interesting candidate.
Status | Terminated |
Enrollment | 23 |
Est. completion date | July 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - man or woman - age = 18 years - signed a written informed consent - Social security coverage - have all the necessary signs for a PNA diagnosis - whose ranking to PNA-1, PNA or PNA-2-3 is possible Fever = 38.5 ° C - Or the possibility of hypothermia in the single case of PNA-3 - Of a spontaneous pain of one or both sides - Pain caused to the costovertebral angle - And presence of leukocyturia GB/mm3 = 10 with or without nitriturie - Imaging examination at least abdominopelvic ultrasound (EAP) or CT, excluding any other possible diagnoses Exclusion Criteria: - Pregnant or lactating women because they are also mother-child care - Patients refusing to provide reliable contact information, especially phone number - In general, patients with significant cognitive impairment, no entourage, because adherence to guidelines, treatment and monitoring can be very random - The PNA 3 emergency situation such as no time to start antibiotics ("antibiotic Emergency" = 30 to 60 minutes between arrival and administration of antibiotics) or reanimation can not be accepted, especially if a third person was required to sign the consent. The typical example is the patient with septic shock. - Inclusion in another study, - Any suspected nosocomial PNA, defined as any PNA appeared within 48 hours of discharge from a medical institution. The residential facilities for the frail elderly (retirement homes), and other institutions for the aged, not medicalized, are not affected by this limitation. - All uptake within 24 hours of: ciprofloxacin, ofloxacin, levofloxacin, or ceftriaxone. Taking antibiotics considered less active in E. coli (amoxicillin ± clavulanate, trimethoprim) or ineffective in the pna (norfloxacin), before arriving at the hospital regardless of its duration, is not an exclusion criteria. The approach should remain similar to those of other patients, and possible exclusion imposed only if the initial bacteriuria is = 103 CFU / ml. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | Hôpital Ambroise Paré | Boulogne Billancourt | Ile de France |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The overall cure rate. | This is the clinical and bacteriological cure, defined by apyrexia, the disappearance of pain and bacteriuria <103 CFU / ml at the 3 follow-up consultations till 45 ± 3 days after the first day of inclusion (day 0), 6 weeks tracking in total. | 50 months | Yes |
Secondary | 1) Evaluation in the two arms of the PNA-2 and PNA-1 classes | Evaluation in the two arms of the PNA-2 and PNA-1 classes: The rate of complications related to the strategy, including aggravation of infection and initial misdiagnosis Changes and duration of antibiotic therapy The rate of secondary hospitalizations The recovery time of the previous activity Rates of pro-ADM |
50 months | Yes |
Secondary | 2) Evaluation in the PNA-3 category | In the PNA-3 category: duration of antibiotic therapy and hospitalization. | 50 months | Yes |
Secondary | 3)For the three categories | For the three categories: evidence of association between clinical symptoms, history, age and sex, the rate of pro-ADM and healing to construct a prognostic score. | 50 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282006 -
Treating Pyelonephritis an Urosepsis With Pivmecillinam
|
Phase 4 | |
Completed |
NCT02246361 -
Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication
|
Phase 4 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT03275623 -
Management of Sub-Clinical Bacteriuria in Pregnancy
|
Phase 4 | |
Completed |
NCT00210886 -
A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.
|
Phase 3 | |
Completed |
NCT00528476 -
Risk Factors for Recurrent Urinary Tract Infection in Children
|
N/A | |
Completed |
NCT03873701 -
Bedside Ultrasonography in Acute Patients With Suspected Kidney Involvement
|
||
Completed |
NCT00382343 -
A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux
|
Phase 4 | |
Recruiting |
NCT03959163 -
The Validity of the Quick Renal MRI in Pediatric Kidney Disease
|
N/A | |
Completed |
NCT01861353 -
Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children
|
N/A | |
Completed |
NCT01505634 -
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
|
Phase 2 | |
Not yet recruiting |
NCT06128213 -
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
|
Phase 2 | |
Completed |
NCT00210990 -
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
|
Phase 3 | |
Completed |
NCT01345929 -
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
|
Phase 3 | |
Completed |
NCT00258089 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Completed |
NCT01641029 -
Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis
|
N/A | |
Terminated |
NCT00724256 -
Short-term Antibiotic Therapy for Pyelonephritis in Childhood
|
Phase 3 | |
Completed |
NCT00136656 -
Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old
|
Phase 4 | |
Completed |
NCT04594161 -
Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis
|
N/A | |
Completed |
NCT02080182 -
Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.
|
Phase 2 |